Latest From PolyPid Ltd.
Private Company Edition: Nkarta, Passage Bio and Achilles kicked off September with VC deals totaling more than $100m each. Also, Repare raised $82.5m and SutroVax won CARB-X cash.
Keeping Track: Novartis Scores Big Ahead Of US Memorial Day With Approvals For Gene Therapy Zolgensma, Oncologic Piqray
There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.
Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.
- Controlled Release
- Site Specific
- Drug Delivery
- Therapeutic Areas
- Dental & Oral Products
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Wound Healing & Tissue Repair
- Middle East
- Parent & Subsidiaries
- PolyPid Ltd.
- Senior Management
Amir Weisberg, CEO
Dikla C Akselbrad, CFO
Noam Emanuel, PhD, CTO
Jack E Kyiet, COO
Tamar Alon, PhD, MBA, Chief Business Officer
Dan J Gelvan, EVP
Lior Zelikovich, PhD, Head of Development
Moran Cohen, Site Manager
- Contact Info
18 Hasivim Street
P.O. Box 7126 Petach Tikva, 4959376
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.